JHS vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JHS presents as a classic value play with a stable Piotroski F-Score of 5/9 and a significant discount to its Graham Number ($16.31) and Intrinsic Value ($15.77). While the company boasts exceptional profit margins (88.44%) and a sustainable dividend yield of 5.44%, it is hampered by sluggish revenue growth (2.60%) and a completely bearish technical trend (0/100). The valuation is attractive (P/B of 0.90), but the lack of growth catalysts and poor liquidity ratios suggest a potential value trap rather than a growth opportunity.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
JHS vs JPM: Head-to-Head Comparison
This page compares John Hancock Income Securities Trust (JHS) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.